Antiviral drugs should be used to treat H1N1 swine flu only in patients who are hospitalized from the flu or are at high risk of complications.
Antiviral medications should be used to treat H1N1 swine flu only in people who are hospitalized from the flu or are at high risk of complications from it, according to the Centers for Disease Control and Prevention.
At a Sept. 8 news conference, CDC officials announced new guidelines for the use of antivirals, which include oseltamivir and zanamivir. According to the agency, because H1N1 has been mild in most people who contract it, the majority of patients will not need to take antivirals. Those who should receive the drugs if they get swine flu include people with underlying health conditions, such as diabetes or asthma; the elderly; the very young; and pregnant women.
One of the CDC's reasons for determining that most swine flu patients should not receive antivirals is concern over development of H1N1 resistance to them. The guidelines also offer a "watchful waiting" alternative to starting antivirals in high-risk people only exposed to H1N1, foregoing treatment unless symptoms appear. However, the officials stress, upon flu symptom onset, antiviral treatment should begin promptly in these individuals rather than waiting for confirmatory test results.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
2 Commerce Drive
Cranbury, NJ 08512